http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021338664-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19f22977afc5f0eb7e7c3d191ac00013 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 |
filingDate | 2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d934518d1343a4e6962b921b1b1dd22 |
publicationDate | 2021-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2021338664-A1 |
titleOfInvention | Compositions and methods for mitigating aflatoxin b1-induced liver injury |
abstract | A method for providing a therapy to a subject that has been exposed to an Aflatoxin B1 can include administering a compound having a structure of Formula 1 to the subject after exposure to the Aflatoxin B1: n n n n n n n n n n n n wherein: R 1 , R 2 , R 3 , R 4 , R 5 and/or R 6 are each individually a chemical moiety and n is 1, 2, 3, 4, or 5. The compound can be Amprenavir or a derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof. The prodrug can be Amprenavir phosphate. |
priorityDate | 2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 249.